Author response: Different efficacy of propranolol in mice with oxygen-induced retinopathy: Could differential effects of propranolol be related to differences in mouse strains?

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 12, 2012, Pages 7728-7729

  Chen, Jing ^a   Hellstrom, Ann ^b   Smith, Lois E H ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ISOPRENALINE; PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANGIOGENESIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY; TREATMENT RESPONSE; ANIMAL; NOTE; RETROLENTAL FIBROPLASIA;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HUMANS; PROPRANOLOL; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY;

EID: 84872175537     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11199     Document Type: Letter

References (14)

1. Filippi L, Dal Monte M, Bagnoli P. Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? Invest Ophthalmol Vis Sci. 2012;53:7421-7423.
2. Chen J, Joyal JS, Hatton CJ, et al. Propranolol inhibition of beta-adrenergic receptor does not suppress pathologic neovascu-larization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2012;53:2968-2977.
3. Hard AL, Hellstrom A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr. 2011;100:1063-1065.
4. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610-614.
5. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol. 2010; 27:195-196.
6. Filippi L, Cavallero G, Fiorini P, et al. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010;10:83.
7. Fledelius HC. Retinopathy of prematurity in Frederiksborg County 1988-1990. A prospective investigation, an update. Acta Ophthalmol Suppl. 1993;210:59-62.
8. Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthal-mol Soc. 2004;102:233-248; discussion 248-250.
9. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155-170.
10. Schimanski LA, Ali DW, Baker GB, Nguyen PV. Impaired hippocampal LTP in inbred mouse strains can be rescued by beta-adrenergic receptor activation. Eur J Neurosci. 2007;25: 1589-1598.
11. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4:1565-1573.
12. Stahl A, Connor KM, Sapieha P, et al. Computer-aided quantification of retinal neovascularization. Angiogenesis. 2009;12:297-301.
13. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnolli P. Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53:2181-2192.
14. Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of beta(2) -adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317-1329.